1. Home
  2. CYTK vs CAI Comparison

CYTK vs CAI Comparison

Compare CYTK & CAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

SELL

Current Price

$54.70

Market Cap

10.7B

Sector

Health Care

ML Signal

SELL

Logo Caris Life Sciences Inc.

CAI

Caris Life Sciences Inc.

SELL

Current Price

$26.26

Market Cap

9.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CYTK
CAI
Founded
1997
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
9.7B
IPO Year
2004
2025

Fundamental Metrics

Financial Performance
Metric
CYTK
CAI
Price
$54.70
$26.26
Analyst Decision
Buy
Buy
Analyst Count
22
14
Target Price
★ $107.39
$32.46
AVG Volume (30 Days)
1.6M
★ 3.4M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.79
EPS
N/A
★ 0.05
Revenue
$13,368,000.00
★ $812,033,000.00
Revenue This Year
$79.67
$26.84
Revenue Next Year
$172.23
$19.27
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 96.97
52 Week Low
$58.25
$14.19
52 Week High
$88.31
$36.50

Technical Indicators

Market Signals
Indicator
CYTK
CAI
Relative Strength Index (RSI) 52.28 56.82
Support Level $63.96 $16.52
Resistance Level $66.93 $36.50
Average True Range (ATR) 2.04 1.91
MACD 0.50 -0.06
Stochastic Oscillator 86.71 48.75

Price Performance

Historical Comparison
CYTK
CAI

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CAI Caris Life Sciences Inc.

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Share on Social Networks: